Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
PainReform ( (PRFX) ) just unveiled an update.
On August 13, 2025, PainReform Ltd. announced the completion of its strategic investment in LayerBio, Inc., acquiring a majority equity interest. This acquisition positions PainReform to enter the $9 billion global cataract surgery market with LayerBio’s OcuRing™-K, a non-opiate, non-steroidal postoperative NSAID drug delivery system. The OcuRing™-K technology offers a ‘dropless’ solution for cataract surgery, addressing the growing demand for simplified postoperative care and potentially improving patient outcomes by eliminating the need for daily eye drops. This move is expected to strengthen PainReform’s market position and expand its reach into additional ophthalmic and surgical indications.
The most recent analyst rating on (PRFX) stock is a Hold with a $48.00 price target. To see the full list of analyst forecasts on PainReform stock, see the PRFX Stock Forecast page.
Spark’s Take on PRFX Stock
According to Spark, TipRanks’ AI Analyst, PRFX is a Underperform.
PainReform faces substantial financial hurdles, primarily due to its lack of revenue and persistent losses, making its financial performance the most significant negative factor. Technical analysis reflects a neutral to slightly bearish outlook, while valuation metrics underscore the company’s financial struggles with a negative P/E ratio. Overall, the stock presents high risks without notable strengths to offset these concerns.
To see Spark’s full report on PRFX stock, click here.
More about PainReform
PainReform Ltd. is a company focused on reformulating established therapeutics and developing AI-driven energy optimization technologies through its DeepSolar platform. The company’s pharmaceutical programs aim to provide prolonged post-surgical pain relief with a proprietary extended-release drug-delivery system, minimizing the need for repeated dosing and reducing opioid reliance. Additionally, PainReform offers advanced software solutions for energy consumption monitoring and optimization, particularly in solar-integrated environments, reflecting its strategic commitment to healthcare and sustainable energy sectors.
Average Trading Volume: 163,743
Technical Sentiment Signal: Strong Sell
Current Market Cap: $2.72M
For detailed information about PRFX stock, go to TipRanks’ Stock Analysis page.